← FDA DRUG APPROVALS

FDA ANDA · ANDA206812

FONDAPARINUX SODIUM

Sponsor: HENGRUI PHARMA

APPLICATION
ANDA206812
TYPE
ANDA
ORIGINAL APPROVAL
2018-05-15
LATEST ACTION
2018-05-15
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

FONDAPARINUX SODIUMDiscontinued
FONDAPARINUX SODIUM 10MG/0.8ML (10MG/0.8ML) · SOLUTION · SUBCUTANEOUS
FONDAPARINUX SODIUMDiscontinued
FONDAPARINUX SODIUM 5MG/0.4ML (5MG/0.4ML) · SOLUTION · SUBCUTANEOUS
FONDAPARINUX SODIUMDiscontinued
FONDAPARINUX SODIUM 7.5MG/0.6ML (7.5MG/0.6ML) · SOLUTION · SUBCUTANEOUS
FONDAPARINUX SODIUMDiscontinued
FONDAPARINUX SODIUM 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION · SUBCUTANEOUS

Approval history

2018-05-15UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →